Skip to content

Zito Partners

  • Home
  • About Us
  • News
  • IPZ

Alopexx Interviewed by OncLive at ASH

  • Post author By Zito Partners
  • Post date December 15, 2015
  • Categories In All News, Client News

Dr. Vlock on Anti–CD20 Interleukin-2 Immunocytokine in NHL

Daniel R. Vlock, MD, founder and CEO, Alopexx Enterprises, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Read more here.

  • Tags alopexx, ASH, daniel vlock, hematology, onclive, oncology
  • Open Twitter in a new tab
  • Open LinkedIn in a new tab
  • Home
  • About Us
  • News
  • IPZ
© 2025  Zito Partners, LLC. All rights reserved.